Have the FDA's Warnings Affected Flyoroquinolone Prescribing in the U.S.?

摘要

While not specifically proving causation, the temporal association between the May 2016 FDA warning and the drop in FQ prescription fills strongly suggests that these warnings meaningfully affected FQ prescribing for outpatients. The authors conclude that FDA safety warnings may prove useful for influencing outpatient antimicrobial stewardship practices (particularly important as broad-spectrum oral antibiotics become increasingly available). Will FDA warnings about escalating antimicrobial resistance carry as nruch weight in changing prescribing practices?